Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2015

NxSTAGE MEDICAL, INC.

(Exact name of registrant as specified in its charter)



Delaware	000-51567	04-3454702
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

350 Merrimack Street, Lawrence, MA		01843
(Address of principal executive offices)		(Zip Code)

(978) 687-4700

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 2.02	Results of Operations and Financial Condition.

On August 6, 2015, NxStage Medical, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2015, which is furnished as Exhibit 99 to this report.

The information furnished in this report, including Exhibit 99, shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

The exhibit listed in the Exhibit Index is furnished as part of this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NxStage Medical, Inc.

By: /s/ Matthew W. Towse

Matthew W. Towse

Chief Financial Officer

Date: August 6, 2015

EXHIBIT INDEX



Exhibit No.			Description
99			NxStage Medical's press release dated August 6, 2015.

NXSTAGE REPORTS RECORD SECOND QUARTER FINANCIAL RESULTS AND IMPROVES FINANCIAL GUIDANCE FOR 2015


•	Revenue Increases to $80.3 million, up 8% from Q2'14


•	Home Revenue Increases to $44.8 million, up 16% from Q2'14


•	Products Business Achieves Profitability Goal Ahead of Plan


•	Company to Begin Launching Innovative Pipeline Next Year


•	Company Renews Blood Tubing Distribution Agreement

LAWRENCE, Mass., August 6, 2015, --NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported second quarter financial results at and above the top end of its guidance ranges.

Revenue for the second quarter of 2015 increased 8 percent to $80.3 million, compared with revenue of $74.1 million for the second quarter of 2014. The Company's revenue guidance range for the second quarter was $79.0 million to $80.5 million. The increase was driven by the System One segment which consists of Home and Critical Care.

Home revenue increased 16 percent to $44.8 million for the second quarter of 2015 compared with revenue of $38.5 million for the second quarter of 2014.

Critical Care revenue increased 18 percent to $14.6 million for the second quarter of 2015 compared with revenue of $12.4 million for the second quarter of 2014.

Consistent with the Company's guidance, In-center revenue was $18.6 million for the second quarter of 2015 compared with revenue of $21.0 million for the second quarter of 2014.

Net loss attributable to NxStage Medical, Inc.'s stockholders improved to $5.3 million for the second quarter of 2015 compared with a net loss of $7.1 million for the second quarter of 2014. NxStage Medical, Inc.'s net loss for the second quarter of 2015 was better than its guidance for a net loss of $5.5 million to $7.0 million and included $1.0 million of income from operations from the Products Business and $5.8 million in losses from operations from the Services segment, NxStage Kidney Care, less noncontrolling interest.

Separately, the Company announced that its blood tubing distribution agreement with Baxter International, Inc. has been renewed through December of 2016.

"NxStage's solid performance proves our commitment to strong, profitable long-term growth," stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage. "Consistent with our growth strategy, we are driving increased demand for our therapy options and giving patients and clinicians more flexibility to meet both their clinical and lifestyle needs. In turn, we have been able to successfully execute on key financial metrics and strategic initiatives. We expect to surprise and delight our patients and customers with the launch of new game-changing technology starting next year that we believe will further extend our market leadership and fuel long-term growth."

Guidance:

"After a strong first half of the year, we expect to achieve the top end of our annual revenue guidance which was originally set to be between $324 million and $328 million," stated Matthew W. Towse, Chief Financial Officer. "Since early 2014, we have indicated that one of our key financial goals was to achieve sustainable operating income in the Products Business. Q2 marks our third consecutive quarter of

profitable operations in that business and we remain confident in our ability to sustain this performance moving forward. Taken together with our expectations for the remainder of the year, we are improving and narrowing our annual net loss guidance to be in a range of $18.0 million to $20.0 million versus our previous guidance for a net loss in the range of $20.0 million to $24.0 million, and dramatically reducing our targeted annual cash usage to approximately $10 million, which is about half our original projection and one-third of our cash usage in 2014."

For the third quarter, the Company expects revenue to be between $82 million and $83 million, and a net loss in the range of $4.5 million to $5.5 million. The Company's net loss guidance reflects expectations for continued operating income from the Products Business offset by the Company's continued investment in NxStage Kidney Care.

Conference Call:

NxStage will also host a conference call today at 9:00 a.m. Eastern Time to discuss its second quarter financial results. To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international). The call will also be webcast LIVE and can be accessed via the investor relations section of the Company’s website at http://ir.nxstage.com.

A replay of the conference call will be available two hours after the completion of the call through August 14, 2015. To access the replay, dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 77465339. An online archive of the conference call can be accessed via the investor relations section of the Company’s website at http://ir.nxstage.com.

About the NxStage System One

The NxStage System One is the first and only portable hemodialysis machine cleared specifically by the U.S. Food & Drug Administration (FDA) for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. The System One is also used to provide a range of flexible therapy options in more traditional care settings such as hospitals and dialysis centers. Its safety and efficacy have been demonstrated by experience with more than 10 million treatments with thousands of patients around the world. www.nxstage.com.

About NxStage

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin, and cash usage, anticipated success and timing of new product introductions, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products domestically and internationally, growth in home and/or more frequent hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and more frequent hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Healthcare Partners Inc. and Fresenius Medical Care, including in response to the Company's NxStage Kidney Care initiative, unanticipated difficulties in developing and commercializing new products, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its most recent quarterly or annual report.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Contact:

Kristen K. Sheppard, Esq.

VP, Investor Relations

ksheppard@nxstage.com

NxStage Medical, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(in thousands, except per share data)

(unaudited)



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014

Revenues	$	80,316		$	74,083		$	159,798		$	146,304
Cost of revenues	49,452			46,553			98,808			89,840
Gross profit	30,864			27,530			60,990			56,464
Operating expenses:
Selling and marketing	14,518			13,589			29,066			26,807
Research and development	6,622			5,708			12,496			10,842
Distribution	6,255			6,485			12,626			13,035
General and administrative	8,585			8,399			17,497			17,220
Total operating expenses	35,980			34,181			71,685			67,904
Loss from operations	(5,116		)	(6,651		)	(10,695		)	(11,440		)
Other expense:
Interest expense	(242		)	(195		)	(483		)	(393		)
Other income (expense), net	37			(17		)	301			6
	(205		)	(212		)	(182		)	(387		)
Net loss before income taxes	(5,321		)	(6,863		)	(10,877		)	(11,827		)
Provision for income taxes	273			332			580			678
Net loss	(5,594		)	(7,195		)	(11,457		)	(12,505		)
Less: Net loss attributable to noncontrolling interests	(267		)	(82		)	(472		)	(117		)
Net loss attributable to stockholders of NxStage Medical, Inc.	$	(5,327	)	$	(7,113	)	$	(10,985	)	$	(12,388	)

Net loss per share, basic and diluted	$	(0.08	)	$	(0.12	)	$	(0.17	)	$	(0.20	)
Weighted-average shares outstanding, basic and diluted	63,288			61,469			63,059			61,484

Other comprehensive (loss) income	(154		)	173			(930		)	355
Total comprehensive loss	(5,748		)	(7,022		)	(12,387		)	(12,150		)
Less: Comprehensive loss attributable to noncontrolling interests	(267		)	(82		)	(472		)	(117		)
Total comprehensive loss attributable to stockholders of NxStage Medical, Inc.	$	(5,481	)	$	(6,940	)	$	(11,915	)	$	(12,033	)

NxStage Medical, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share data)

(unaudited)



	June 30,			December 31,
	2015			2014

ASSETS
Current assets:
Cash and cash equivalents	$	48,350		$	52,884
Accounts receivable, net	26,401			24,099
Inventory	43,372			45,401
Prepaid expenses and other current assets	6,254			6,767
Total current assets	124,377			129,151
Property and equipment, net	64,443			66,574
Field equipment, net	21,104			21,118
Deferred cost of revenues	33,821			34,039
Intangible assets, net	12,950			14,370
Goodwill	41,817			41,817
Other assets	2,875			2,657
Total assets	$	301,387		$	309,726
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	12,790		$	13,845
Accrued expenses	22,961			24,653
Current portion of long-term debt	249			93
Other current liabilities	4,858			6,165
Total current liabilities	40,858			44,756
Deferred revenues	51,716			52,943
Long-term debt	1,841			848
Other long-term liabilities	18,522			19,624
Total liabilities	112,937			118,171
Commitments and contingencies
Stockholders’ equity:
Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2015 and December 31, 2014	—			—
Common stock: par value $0.001, 100,000,000 shares authorized; 64,232,634 and 63,429,005 shares issued as of June 30, 2015 and December 31, 2014, respectively	64			63
Additional paid-in capital	602,628			593,073
Accumulated deficit	(398,473		)	(387,488		)
Accumulated other comprehensive loss	(3,122		)	(2,192		)
Treasury stock, at cost: 815,779 and 772,273 shares as of June 30, 2015 and December 31, 2014, respectively	(13,734		)	(12,989		)
Total NxStage Medical, Inc. stockholders' equity	187,363			190,467
Noncontrolling interest	1,087			1,088
Total stockholders' equity	188,450			191,555
Total liabilities and stockholders’ equity	$	301,387		$	309,726

NxStage Medical, Inc.

Cash Flows from Operating Activities

(in thousands)

(unaudited)



	Six Months Ended June 30,
	2015			2014

Cash flows from operating activities:
Net loss	$	(11,457	)	$	(12,505	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	15,473			13,343
Stock-based compensation	6,590			5,740
Other	813			450
Changes in operating assets and liabilities:
Accounts receivable	(2,315		)	(10,927		)
Inventory	(8,023		)	(17,523		)
Prepaid expenses and other assets	169			(550		)
Accounts payable	(641		)	7,948
Accrued expenses and other liabilities	(2,036		)	1,206
Deferred revenues	(957		)	(1,395		)
Net cash used in operating activities	$	(2,384	)	$	(14,213	)

NxStage Medical, Inc.

Revenues by Segment

(in thousands)

(unaudited)



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
System One segment
Home	$	44,789		$	38,488		$	88,287		$	74,983
Critical Care	14,631			12,422			30,713			27,114
Total System One segment	59,420			50,910			119,000			102,097
In-Center segment	18,563			21,003			36,430			39,919
Other	1,857			1,943			3,704			3,997
Products subtotal	79,840			73,856			159,134			146,013
Services segment	1,144			428			1,814			544
Elimination of intersegment revenues	(668		)	(201		)	(1,150		)	(253		)
Total	$	80,316		$	74,083		$	159,798		$	146,304

NxStage Medical, Inc.

Segment Financial Performance

(in thousands)

(unaudited)



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Products (System One, In-Center and Other)
Revenues	$	79,840		$	73,856		$	159,134		$	146,013
Gross profit	$	34,781		$	28,925		$	68,487		$	59,106
Gross margin percentage	44		%	39		%	43		%	40		%
Income (Loss) from operations	$	955		$	(3,405	)	$	1,158		$	(5,239	)
Services
Revenues	$	1,144		$	428		$	1,814		$	544
Gross profit	$	(3,917	)	$	(1,395	)	$	(7,497	)	$	(2,642	)
Gross margin percentage	n/a			n/a			n/a			n/a
Loss from operations	$	(6,071	)	$	(3,246	)	$	(11,853	)	$	(6,201	)
Eliminations
Elimination of intersegment revenues	$	(668	)	$	(201	)	$	(1,150	)	$	(253	)
Total Company
Revenues	$	80,316		$	74,083		$	159,798		$	146,304
Gross profit	$	30,864		$	27,530		$	60,990		$	56,464
Gross margin percentage	38		%	37		%	38		%	39		%
Loss from operations	$	(5,116	)	$	(6,651	)	$	(10,695	)	$	(11,440	)